AngioDynamics, Inc. (NASDAQ:ANGO) investors should pay attention to a decrease in enthusiasm from smart money lately.
In the eyes of most stock holders, hedge funds are seen as worthless, outdated investment tools of the past. While there are more than 8000 funds with their doors open at the moment, we at Insider Monkey look at the bigwigs of this club, around 450 funds. Most estimates calculate that this group oversees the lion’s share of all hedge funds’ total capital, and by paying attention to their highest performing picks, we have discovered a number of investment strategies that have historically outperformed the S&P 500 index. Our small-cap hedge fund strategy outpaced the S&P 500 index by 18 percentage points per annum for a decade in our back tests, and since we’ve started sharing our picks with our subscribers at the end of August 2012, we have outpaced the S&P 500 index by 24 percentage points in 7 months (explore the details and some picks here).
Equally as integral, bullish insider trading activity is another way to break down the investments you’re interested in. Obviously, there are many incentives for a corporate insider to drop shares of his or her company, but just one, very clear reason why they would initiate a purchase. Various academic studies have demonstrated the valuable potential of this method if shareholders understand where to look (learn more here).
With all of this in mind, it’s important to take a peek at the recent action encompassing AngioDynamics, Inc. (NASDAQ:ANGO).
What does the smart money think about AngioDynamics, Inc. (NASDAQ:ANGO)?
At the end of the fourth quarter, a total of 10 of the hedge funds we track were long in this stock, a change of -17% from the third quarter. With hedge funds’ sentiment swirling, there exists a select group of noteworthy hedge fund managers who were upping their holdings meaningfully.
According to our comprehensive database, James E. Flynn’s Deerfield Management had the biggest position in AngioDynamics, Inc. (NASDAQ:ANGO), worth close to $26.8 million, accounting for 1.5% of its total 13F portfolio. On Deerfield Management’s heels is Broadfin Capital, managed by Kevin Kotler, which held a $23 million position; the fund has 5.7% of its 13F portfolio invested in the stock. Other hedge funds with similar optimism include Chuck Royce’s Royce & Associates, SAC Subsidiary’s CR Intrinsic Investors and Mario Gabelli’s GAMCO Investors.
Judging by the fact that AngioDynamics, Inc. (NASDAQ:ANGO) has faced declining sentiment from the aggregate hedge fund industry, it’s easy to see that there is a sect of hedgies that elected to cut their full holdings last quarter. It’s worth mentioning that Sander Gerber’s Hudson Bay Capital Management dropped the biggest stake of the “upper crust” of funds we monitor, worth close to $0.6 million in stock., and Paul Tudor Jones of Tudor Investment Corp was right behind this move, as the fund dropped about $0.1 million worth. These moves are interesting, as aggregate hedge fund interest fell by 2 funds last quarter.
Insider trading activity in AngioDynamics, Inc. (NASDAQ:ANGO)
Insider purchases made by high-level executives is at its handiest when the company in question has seen transactions within the past six months. Over the latest half-year time period, AngioDynamics, Inc. (NASDAQ:ANGO) has seen 4 unique insiders buying, and 1 insider sales (see the details of insider trades here).
Let’s also examine hedge fund and insider activity in other stocks similar to AngioDynamics, Inc. (NASDAQ:ANGO). These stocks are Vascular Solutions, Inc. (NASDAQ:VASC), OraSure Technologies, Inc. (NASDAQ:OSUR), Merit Medical Systems, Inc. (NASDAQ:MMSI), Antares Pharma Inc (NASDAQ:ATRS), and Atrion Corporation (NASDAQ:ATRI). This group of stocks are the members of the medical instruments & supplies industry and their market caps match ANGO’s market cap.